Literature DB >> 26148522

Hepatectomy Offers Superior Survival Compared with Non-surgical Treatment for ≤ 3 Metastatic Tumors with Diameters < 3 cm from Gastric Cancer: A Retrospective Study.

Yu Ohkura1, Hisashi Shinohara2,3, Shusuke Haruta1, Masaki Ueno1, Masaji Hashimoto1, Yoshiharu Sakai4, Harushi Udagawa1.   

Abstract

BACKGROUND: A consensus has almost been reached in favor of hepatic resection for colorectal cancer metastases. It remains unclear whether resection of gastric cancer metastases in the liver is justified. The purpose of this study was to assess the survival benefit of surgical resection for gastric cancer metastases confined to the liver.
METHODS: We reviewed the clinicopathological features and outcome of 107 patients with liver metastases without other non-curative factors from the case records of 5437 gastric cancer patients. These subjects included 34 synchronous cases with tumors present at the time of gastrectomy and 73 metachronous cases with new lesions that appeared after radical gastrectomy.
RESULTS: Hepatectomies were performed in nine synchronous and four metachronous cases that had ≤3 tumors with diameters <3 cm. The overall survival rates after hepatectomy were significantly higher than those in eligible candidates who did not receive hepatectomy despite having comparable metastatic status (synchronous, n = 8, p = 0.009; metachronous, n = 24, p = 0.016). The survival rate of patients who underwent hepatectomy for synchronous metastases was not inferior to that of patients who underwent hepatectomy for metachronous metastases. The median disease-free interval in metachronous cases was significantly shorter in patients who did not undergo resection than those who underwent resection. However, multivariate analyses revealed that hepatectomy was the only significant (p = 0.001) prognostic factor whereas DFI was not.
CONCLUSIONS: Hepatectomy for ≤3 metastatic tumors with diameters <3 cm offered superior survival compared with non-surgical treatment even for metastases detected synchronously or within a short period after radical gastrectomy.

Entities:  

Mesh:

Year:  2015        PMID: 26148522     DOI: 10.1007/s00268-015-3151-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

Review 1.  Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines.

Authors:  Yasuhiro Kodera; Kazumasa Fujitani; Norimasa Fukushima; Seiji Ito; Kei Muro; Norifumi Ohashi; Takaki Yoshikawa; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2014-04       Impact factor: 7.370

2.  Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.

Authors:  Yoshihiro Sakamoto; Takeshi Sano; Kazuaki Shimada; Minoru Esaki; Makoto Saka; Takeo Fukagawa; Hitoshi Katai; Tomoo Kosuge; Mitsuru Sasako
Journal:  J Surg Oncol       Date:  2007-06-01       Impact factor: 3.454

3.  Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Aaron U Blackham; Gregory B Russell; John H Stewart; Konstantinos Votanopoulos; Edward A Levine; Perry Shen
Journal:  Ann Surg Oncol       Date:  2014-03-11       Impact factor: 5.344

4.  Benefits and limits of hepatic resection for gastric metastases.

Authors:  S Ambiru; M Miyazaki; H Ito; K Nakagawa; H Shimizu; H Yoshidome; Y Shimizu; N Nakajima
Journal:  Am J Surg       Date:  2001-03       Impact factor: 2.565

5.  Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Authors:  Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

Authors:  Gianluca Masi; Fotios Loupakis; Lisa Salvatore; Lorenzo Fornaro; Chiara Cremolini; Samanta Cupini; Andrea Ciarlo; Francesca Del Monte; Enrico Cortesi; Domenico Amoroso; Cristina Granetto; Gabriella Fontanini; Elisa Sensi; Cristiana Lupi; Michele Andreuccetti; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2010-08-09       Impact factor: 41.316

7.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection.

Authors:  Ken Shirabe; Mitsuo Shimada; Takashi Matsumata; Hidefumi Higashi; Yohichi Yakeishi; Shigeki Wakiyama; Yasuharu Ikeda; Takuhiro Ezaki; Shingo Fukuzawa; Kenji Takenaka; Keishi Kishikawa; Tetsuo Ikeda; Ken-ichi Taguchi; Yoshihiko Maehara; Keizo Sugimachi
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

9.  Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases.

Authors:  Y Yonemura; N Matuki; H Sakuma; K Katayama; T Sawa; T Fujimura; S Ohyama; K Miwa; I Miyazaki; M Tanaka
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

10.  Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors.

Authors:  T Ochiai; M Sasako; S Mizuno; T Kinoshita; T Takayama; T Kosuge; S Yamazaki; K Maruyama
Journal:  Br J Surg       Date:  1994-08       Impact factor: 6.939

View more
  5 in total

1.  Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival.

Authors:  Maria José Temido; Rui Caetano Oliveira; Ricardo Martins; Marco Serôdio; Beatriz Costa; César Carvalho; Eva Santos; Luís Ferreira; Paulo Teixeira; Maria Augusta Cipriano; José Guilherme Tralhão; Henrique Alexandrino
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

2.  Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta-Analysis.

Authors:  Paschalis Gavriilidis; Keith J Roberts; Nicola de'Angelis; Robert P Sutcliffe
Journal:  J Clin Med Res       Date:  2019-07-27

Review 3.  Surgery Strategies for Gastric Cancer With Liver Metastasis.

Authors:  Zai Luo; Zeyin Rong; Chen Huang
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

4.  Identifying Optimal Surgical Intervention-Based Chemotherapy for Gastric Cancer Patients With Liver Metastases.

Authors:  Min Sun; Hangliang Ding; Zhiqiang Zhu; Shengsheng Wang; Xinsheng Gu; Lingyun Xia; Tian Li
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 5.  Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors.

Authors:  Gianpaolo Marte; Andrea Tufo; Francesca Steccanella; Ester Marra; Piera Federico; Angelica Petrillo; Pietro Maida
Journal:  J Clin Med       Date:  2021-03-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.